NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc.
Danish Breast Cancer Cooperative Group
University of Utah
EirGenix, Inc.
Jiangsu HengRui Medicine Co., Ltd.
National Institute of Cancerología
Foresee Pharmaceuticals Co., Ltd.
Foresee Pharmaceuticals Co., Ltd.